Henry Ford Hospital cardiologists are first in the U.S. to implant circulatory support device
Cardiologists at Henry Ford Hospital are first in the U.S. and second in the world to implant a circulatory support device that is being investigated in a clinical trial for patients hospitalized with acute decompensated heart failure (ADHF) and worsening kidney function, a condition known as cardiorenal syndrome.
The Aortix™ System from Procyrion, Inc. is an intra-aortic axial flow pump, which is deployed via a femoral catheter to the descending aorta. This tiny pump, thinner than the size of a #2 pencil, is designed to relieve some of the heart s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.
Edison resident named medical director of Atlantic Health Systemâs Heart Success program
Edison resident named medical director of Atlantic Health Systemâs Heart Success program ×
Atlantic Health System announced that Abhishek Singh, MD, PhD, has been named medical director of Atlantic Health Systemâs Heart Success program, which cares for patients with advanced heart failure.
Singh, a longtime Edison resident, is triple board-certified in internal medicine, cardiology, and advanced heart failure and transplant cardiology.
âAs one of the nationâs leading cardiology and cardiothoracic surgery programs, we take great pride in being able to offer our patients the most advanced, subspecialized evidence-based care,â Linda D. Gillam, MD, MPH, MACC, Dorothy and Lloyd Huck Chair, Department of Cardiovascular Medicine and medical director, Cardiovascular Service Line, Morristown Medical Center/Atlantic Health System, said in a prepared statement. �
Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology s 70th Annual Scientific Session.
Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A
Cardiol Therapeutics Inc. (
a clinical-stage biotechnology company
focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Management s Discussion and Analysis for the year ended December 31, 2020. Both are available under the Company s profile on SEDAR at www.sedar.com and on the Company s website at www.cardiolrx.com.
David Elsley, President and Chief Executive Officer of Cardiol, commented: 2020 was a very exciting year for Cardiol Therapeutics. We made extraordinary progress in our research and clinical development programs, while significantly strengthening our financial position. We are particularly excited about the progress made across our research and development programs supporting the development of CardiolRx, our pharmaceutically produced extra-strength oral f
ISHLT s First All Virtual Annual Meeting to Kick off This Month
ISHLT2021 provides live and on-demand education for the advanced heart and lung failure community
News provided by
Share this article
Share this article
ADDISON, Texas, April 1, 2021 /PRNewswire/ The International Society of Heart and Lung Transplantation (ISHLT) will host its
41
st Annual Meeting & Scientific Sessions on 24-28 April, 2021. The all-virtual event will include educational content spanning the breadth of clinical practice and research concerning heart and lung transplantation, advanced heart and lung disease, mechanical circulatory support, and pulmonary vascular disease. The historic and inaugural virtual 41
st Annual Scientific Meeting of the ISHLT is just weeks away, says